BENEFICIAL EFFECTS OF ADDING SPIRONOLACTONE TO ANTIHIPERTENSIVE TREATMENT IN TYPE 2 DIABETES NEPHROPATHY
{"Image DocumentName": "BENEFICIAL EFFECTS OF ADDING SPIRONOLACTONE TO ANTIHIPERTENSIVE TREATMENT IN TYPE 2 DIABETES NEPHROPATHY", "Image ImageDescription": "Crossover study: (8 weeks per period) - Spironolactone 25 mg/day vs. - Placebo. -20 patients with type 2 DM. -Overt nephropathy. -Full doses of inhibition on RASS. Albuminuria. p < (g/24 hours) 0.5. Placebo. Spironolactone. Rossing et. al. Diabetes Care 2005.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}